These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20740678)

  • 41. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TRIPS: whose interests are being served?
    Kamal M; Bailey M
    Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
    [No Abstract]   [Full Text] [Related]  

  • 43. Taking the fight to their realm: the role of patent oppositions in the struggle for access to medicines.
    Park C
    HIV AIDS Policy Law Rev; 2006 Dec; 11(2-3):84-5. PubMed ID: 17375435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS.
    Curti AM
    Am J Law Med; 2001; 27(4):469-85. PubMed ID: 11837145
    [No Abstract]   [Full Text] [Related]  

  • 45. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
    Van Puymbroeck RV
    J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
    Sampat BN; Amin T
    J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

  • 49. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
    Castro A; Westerhaus M
    Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AIDS, essential medicines, and compulsory licensing.
    Berman D
    J Int Assoc Physicians AIDS Care; 1999 Apr; 5(4):24-5. PubMed ID: 11367046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Global patent police block cost-reduction efforts.
    Kasper T
    GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mixed WTO ruling on generic drug development.
    Elliott R
    Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):38-42, 40-4. PubMed ID: 11833195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A one-time-only combination: Emergency medicine exports and the TRIPS agreement under Canada's access to medicines regime.
    Weber A; Mills L
    Health Hum Rights; 2010 Jun; 12(1):109-22. PubMed ID: 20930258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. WTO ministerial conference adopts declaration on TRIPS and public health.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Mar; 6(3):50-2. PubMed ID: 14979260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TRIPS-plus and access to medicines in China.
    Chen J; Nie X; Yao P; Shi L
    J Public Health Policy; 2013 May; 34(2):226-38. PubMed ID: 23552834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Big-pharmaceuticalisation: clinical trials and Contract Research Organisations in India.
    Sariola S; Ravindran D; Kumar A; Jeffery R
    Soc Sci Med; 2015 Apr; 131():239-46. PubMed ID: 25476783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Production of low cost AIDS drugs to continue in Brazil.
    Reprod Health Matters; 2001 Nov; 9(18):178. PubMed ID: 11803899
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.